PDF(Pubmed)
Abstract：
Overall outcomes for multiple myeloma have improved due to the availability of new therapies, but patients with relapsed/refractory multiple myeloma harbouring certain factors continue to pose a therapeutic challenge. These challenging features include high-risk cytogenetics, renal impairment, patient characteristics such as age and frailty, and extramedullary disease. Prior refractory status and number of prior lines add further complexity to the treatment of these patients. While newer regimens are available and have suggested efficacy in these patient populations through subgroup analyses, differences in trial definitions and cut-offs make meaningful comparisons difficult. This review aims to examine the available clinical trial data for patients with high-risk cytogenetics, renal impairment, age and frailty and extramedullary disease.
摘要：
由于新的治疗方法的出现，多发性骨髓瘤的总体结果有所改善。但具有某些因素的复发/难治性多发性骨髓瘤患者仍面临治疗挑战.这些具有挑战性的特征包括高风险的细胞遗传学，肾功能损害，患者特征，如年龄和虚弱，和髓外疾病。先前的难治性状态和先前的线的数量进一步增加了这些患者的治疗的复杂性。虽然有较新的治疗方案，并通过亚组分析提示了这些患者人群的疗效，试验定义和截止值的差异使得有意义的比较变得困难.这篇综述旨在检查高危细胞遗传学患者的可用临床试验数据。肾功能损害，年龄和虚弱和髓外疾病。
